Business Wire

Morinaga Milk Obtains the Registration of "New Food Ingredient" in China for Use of Its Probiotic Bifidobacterium longum BB536 in Infant and Toddler Foods


Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum BB536 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and toddler foods (under the age of three) on 11th May 2022.

This press release features multimedia. View the full release here:

To view this piece of content from, please give your consent at the top of this page.

Morinaga Milk obtains the registration of "New Food Ingredient" in China for use of its probiotic Bifidobacterium longum BB536 in infant and toddler foods on 11th May 2022. (Graphic: Business Wire)

Following a complex and lengthy registration process, the probiotic strain B. longum BB536 meets the highest standards of safety and regulatory compliance and has now completed the approval process for use as an ingredient in infant and toddler milk and food products for children under three years old in China.

“We are extremely proud to have achieved the registration process and consider it an endorsement of the core values of Morinaga Milk’s HRB (human-residential bifidobacteria),” said Dr. Xiao, General Manager of Next Generation Science Institute of Morinaga Milk. “We believe the highest safety standards that we uphold and the strong scientific evidence behind BB536 are what brought us come this far. It has been a long registration process and this approval is an incredible regulatory achievement given the limited number of strains that made it to the list of only 14 strains, including BB536,” he added.

Stringent safety requirements
The “New Food Ingredient” is a regulatory system required for food ingredients to be specifically permitted for use in general foods and infant and toddler foods (<3 years) in China. The registered ingredient must meet certain requirements in terms of nutrition, health, and safety and comply with the regulatory standards in China. To date, there are only 13 registered probiotic strains that can be used in infant and toddler foods in China (six strains in 2011, three in 2016, three in 2020, and one in 2021). The company’s flagship strain, B. longum BB536, is a new addition to the positive list.

Morinaga Milk is the only Japanese company to have obtained the registration for probiotic strains. B. longum BB536 is the company’s second strain to have obtained the approval, following B. breve M-16V in 2016. The company focuses on human-residential bifidobacteria (HRB) – the natural inhabitants of the human gut that exhibit numerous superior physiological functions. Morinaga Milk is committed to develop high quality, safe, reliable and natural probiotics over the past decades and is some way ahead of the curve in HRB research. Both BB536 and M-16V approved by the China’s NHC are the HRB strains.

“The registration process is hard and it should be because the ingredient is dedicated for a vulnerable population. There were some changes in the regulatory frameworks and the safety requirements have become more stringent,” said Dr. Xiao. “However, along with an exceptionally long history of safe use in humans, including infants and young children, the safety and efficacy of BB536 continues to be undoubtedly proven through solid science, leading to the acknowledgement by the China’s NHC,” he added.

All set for use in infant and toddler milk
The Chinese infant and toddler milk market has tripled in size in the 10 years between 2010 and 2019, and is expected to be worth $24.4 billion in 2020, accounting for 47% of the global market (Euromonitor International "Milk Formula in China", September 2021). In addition, the market for infant and toddler milk containing the probiotics Bifidobacterium strain has been on the rise in recent years (Research by Morinaga Milk Industry Co., Ltd. using Mintel GNPD, November 2021).

Under the Morinaga Milk Group's 10-Year Vision, the company aims to achieve a global business sales ratio of 15% or more by the fiscal year ending March 2029. The company is eyeing the giant infant and toddler milk market in China and aims to strengthen its sales in China to help achieve the goal.

Morinaga Milk’s B. longum BB536 has received the FDA GRAS notification in US for use in conventional foods (GRAS Notice No. GRN 000268) and infant and toddler milk (GRAS Notice No. GRN 000877). It has been incorporated in various products worldwide for more than 50 years. Affirmation of this newest registration in China adds value to the company’s proprietary probiotic strain, diversifying its application options available in the infant category.

First B. longum subsp. longum strain in the approval list
Bifidobacterium longum BB536 is a clinically effective, well-established, multifunctional probiotic strain that has a long history of human use (supported by more than 220 scientific studies (as of March 2022)). For half a century, B. longum BB536 has been the superior Human-Residential Bifidobacteria (HRB) probiotic strain that provides a consistent beneficial effect in maintaining human health. Already well known as a leading functional probiotic ingredient for application in food and dietary supplements, Morinaga Milk’s B. longum BB536 is now expanding its application opportunities into the new space, to be specifically permitted for use in infant and toddler milk and foods in China.

“We have always been researching on bifidobacteria, particularly those that naturally occur in the human gut, which are known as the HRB strains,” Dr. Fumiaki Abe, Director of Research and Development Institute of Morinaga Milk. “We obtained the approval for our first HRB strain, B. breve M-16V in 2016, and we are extremely delighted that BB536 has now also passed the stringent process to obtain the Chinese approval pertaining to infant and toddler foods.” “BB536 is the first B. longum subsp. longum strain of HRB in the positive list and its potential is very much exciting,” he added.

Pioneering in bifidobacteria research
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan with a century of history harnessing the nutritional properties of dairy products and its functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at

To view this piece of content from, please give your consent at the top of this page.

Contact information

Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department
Mitsunori Watanabe / Kazuaki Kajikawa
International Division
Junichi Minami / Chyn Boon Wong
Morinaga Milk website:
Morinaga Probiotics Center website:
Morinaga Probiotics Center LinkedIn:

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verdane Partners with Climate Tech Leader Cleanwatts28.6.2022 17:00:00 CEST | Press release

Verdane, the European specialist growth equity investor, through its impact fund Idun, has invested in Cleanwatts, an energy software company on a mission to accelerate global energy decarbonization and alleviate energy poverty. Cleanwatts, which grew year-on-year revenues by 65% in 2021 and expects 2022 revenue growth of more than 200%, offers innovative energy management solutions that help local communities unlock the benefits of optimized renewable energy consumption, generation, storage, trading, and balancing. The partnership, in which Verdane is set to invest up to EUR25m, will draw on Verdane’s deep expertise of scaling SaaS companies, international network and in-house team of operating specialists. Cleanwatts is a Portuguese energy management software company that deploys renewable energy communities (RECs) in countries with advanced legal frameworks and policies that enable the activation of local energy markets. The company operates in Portugal (HQ), Italy, Spain, and the U

Andersen Global Enters New Zealand With the Addition of Two Collaborating Firms28.6.2022 15:30:00 CEST | Press release

Andersen Global establishes tax and legal capabilities in New Zealand through Collaboration Agreements with two Auckland-based firms – law firm Turner Hopkins, and tax and advisory firm Bellingham Wallace. The firms maintain deep connections in the region and will play a pivotal role in driving business and delivering integrated, global solutions to create long-term value for clients. Turner Hopkins was founded in 1923, and for nearly 100 years, has provided full-service capabilities in real estate, corporate and commercial law, litigation, finance, employment law, family, private client, estate and immigration. Turner Hopkins’ interdisciplinary team of professionals has vast experience working across a suite of industries and addressing client needs with comprehensive, customized solutions. “We pride ourselves on our client-focused approach and our commitment to ensuring that we retain the highest caliber of lawyers and professionals, which has allowed us to maintain a competitive edg

Synaptics Selects Allegro DVT’s VVC Compliance Streams28.6.2022 15:30:00 CEST | Press release

Allegro DVT, the leading provider of video codec compliance test suites and semiconductor video IPs, today announced that Synaptics Incorporated, one of the world's largest fabless semiconductor companies, has selected Allegro DVT’s VVC test streams to ensure full compliance of Synaptics’ products with the new emerging VVC video compression standard. Versatile Video Coding (VVC), also known as H.266, is the latest video compression standard that was finalized in 2020. It is the successor of HEVC/H.265 and was conceived to achieve two primary goals: improved compression performance and versatility to support a wide range of video applications such as mobile telephony, VOD, Broadcasting, OTT streaming, videoconferencing, screen content, 360° and scalable coding. Craig Stein, SVP and GM of Mobile and IoT at Synaptics, commented, “The depth and breadth of testing that Allegro’s VVC test suite solution provides ensures Synaptics’ VVC decoder implementation is robust and fully compliant with

TA Announces Advantive, a New Mission-Critical Software Provider for Specialty Manufacturing and Distribution Businesses28.6.2022 15:13:00 CEST | Press release

TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors. This press release features multimedia. View the full release here: Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida. Benoit de la Tour,

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer28.6.2022 15:00:00 CEST | Press release

SonALAsense, a pioneer in the development of SONALA-001 and sonodynamic therapy (SDT), a new drug-device combination developed to manage deadly cancers so patients can become survivors, today announced clinical, organizational and growth updates. It is the only company with SDT in clinical trials. “At SonALAsense, we have been on a journey to develop a non-invasive treatment option for patients with rare brain cancers who often have little hope,” said Mark de Souza, PhD, Founder and Chief Executive Officer. “Today we are excited to announce the culmination of our hard work as we confidently advance SDT into clinical trials as the only non-invasive drug-device combination therapy for the treatment of recurrent glioblastoma multiforme (rGBM) and diffuse intrinsic pontine glioma (DIPG).” Clinical Update SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM. The DIPG trial is actively recruiting and the rGBM clinical trial will begin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom